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Abstract: Carcinoma in situ at the mucosal bronchial resection
margin is a rarely reported event. At present, such histological
findings at the resection margins are classified as R1(is), thus
representing an incomplete resection. A review of the English
literature on the topic was undertaken to try to better define the
significance of such findings and to define possible areas of pro-
spective data acquisition to further define the problem and its
management.
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The presence of carcinoma in situ (CIS) at the mucosalbronchial resection margin has been reported in 0.05 to
2.5% of surgical series.1–13 As per the 7th edition of the
International Association for the Study of Lung Cancer
(IASLC)/American Joint Committee on Cancer (AJCC)/In-
ternational Union Against Cancer (UICC) tumor, node, me-
tastasis (TNM) classification, the letter R may be used as an
additional descriptor to the TNM descriptors to define the
absence or presence of residual tumor at the primary tumor
site after its treatment. After lung cancer resection, the bron-
chial margin status can thus be classified as R0 when the
margin is clean of all malignancy both grossly and micro-
scopically, R1 when the margin is grossly uninvolved but
microscopically positive and R2 in the presence of grossly
positive margins. Presently, the presence of CIS at the bron-
chial margin is considered to represent R1 resected disease
with the added qualifier (is) for in situ. However, it seems that
the prognosis of R1(is) at the bronchial margin is much better
than that of other R1 situations.7,9,11 For that reason, a
proposal by our committee published in 2005 suggested that
the presence of CIS at the bronchial margin be considered an
“uncertain resection,” meaning a resection where there is no
evidence of residual invasive tumor but one that does not
fulfill all the criteria required to be designated as a complete
resection.14 A commentary published in Lung Cancer in 2004
by Kutlu et al.15 even suggested that CIS at the margin should
be considered R0. This controversy surfaced at one of the
meetings of the International Staging Committee of the In-
ternational Association for the Study of Lung Cancer
(IASLC) where the management of such findings by the
members of the Committee was anything but uniform.14 At
one end of the table, one group accepted such margin without
further resection or additional treatment but recommended close
endoscopic follow-up. Others favored surgical revision of the
margin, at times converting a lobectomy to a sleeve lobectomy
or even to a pneumonectomy. Some favored no further resection
but recommended adjuvant radiotherapy to the stump area as
one would consider after a true incomplete resection. Finally, the
potential roles for postresection photodynamic or LIFE-guided
laser therapies to the area were mentioned, if available.
In an effort to possibly establish management guide-
lines for such findings, a review of the available international
literature was undertaken. A secondary objective for this
review is to define potential areas of prospective data set
acquisition that could help us in the future to further define
the problem and its management.
MATERIALS AND METHODS
Surgical Series
CIS at the bronchial resection margin is only described
in a very small percentage of the published series addressing
the topic of residual disease at resection margins. A review of
the English literature of the last 35 years contains 13 articles
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that included and/or described a number of cases with CIS at
the bronchial margin.1–13 These series analyzed populations
ranging from 255 to 4493 resected patients, and incidences of
CIS at the margin varied from 0.02 to 2.4%. Cumulatively,
out of approximately 16,000 resections reported in these
series, 138 cases (0.9%) of CIS at the bronchial margin have
thus been reported (Table 1).
Martini et al.1 in 1974 published a report on 26 cases of
radiologically occult lung cancers diagnosed and treated at
Memorial Sloan-Kettering Cancer Center. In the 13 resected
cases, CIS was found at the bronchial margin in two. Both
patients received adjuvant radiotherapy. At 2 years, one
remained free of disease. The other patient died at 6 years
from a second lung cancer that developed at another site 5
years after initial surgery. The patient had no evidence of
recurrence at the initial margin. In their discussion, the author
suggested that CIS at the bronchial resection margin did not
seem to affect survival and was not a sufficient reason to call
for more extensive surgery.
In 1979, Soorae and Stevenson2 from Belfast reported
on 64 patients with positive margins after 434 consecutive
lung cancer resections in a 5-year period. Ten of these had
CIS at the margin (incidence 2.3%), all 10 of squamous cell
histology, and seven survived 5 years or more after resection
without further therapy (70%, 5-year survival). They con-
cluded that isolated CIS at the margin did not affect survival
contrary to the other three patterns of microscopic bronchial
margin involvement described: direct mucosal extension by
invasive cancer, lymphatic permeation, and involvement of
peribronchial tissues with respective 5-year survival rates of
21%, 0%, and 17%.
In 1982, Law et al.3 from the Royal Brompton Hospital
in London described another nine patients with CIS at their
margin from a retrospective series of 1000 consecutive pa-
tients who underwent lobectomy or pneumonectomy for lung
cancer in a 10-year period (incidence 0.9%). All nine had
squamous histology, and of the eight without mediastinal
nodal involvement, six survived 5 years (75%, 5-year sur-
vival). Similarly, it was concluded that CIS at the margin did
not affect survival.
Heikkila et al.4 in 1986 mentioned five cases of bron-
chial margin CIS included in a series of 44 cases of micro-
scopic positive margins out of 1069 lung cancer resections
performed at the University of Helsinki between 1961 and
1970. No additional detail was available.
A review from Liverpool published in 1988 reported
two cases of CIS at the resected margin out of a resected
population of 560 (incidence 0.35%). Both were of squamous
histology and were alive free of disease 28 and 30 months
after resection.5
At the British Thoracic Society meeting in December
1994, Tan et al.6 from Aberdeen noted six cases of CIS at
the margin out of 255 patients who had lung cancer
resection between 1986 and 1991 (incidence 2.4%). The
survival of these individuals was not different from the
survival of patients with entirely benign histology at their
bronchial margin.
Four years later, Snijder et al.7 from the Netherlands
reported on a series of 834 resected stages I non-small cell
lung cancer (NSCLC). Twelve had CIS at the bronchial
margin (incidence 1.43%). Three of these were adenocarci-
noma, the balance were of squamous cell histology. Local
recurrences were noted in five of the 12 CIS patients, and
75% of CIS patients experienced a recurrence of some sort,
significantly more than in the true R0 group. Survival of this
R1(is) group at 5 years was however 58%, similar to the
survival of the R0 group at 54% and more than double the
survival of the other R1 subgroup (i.e., non-CIS) at 27%.
Having restricted their report solely to patients with N0
disease, this analysis truly eliminated the confounding N
status in their evaluation of how marginal CIS may affect
survival.
The same year, Lacasse et al.8 of the Canadian Lung
Oncology Group identified three patients with CIS at the



















Martini et al.1 1947–1972 26 2 2 0 NA
Soorae and Stevenson2 1968–1972 434 10 10 2.3 NA 70
Law et al.3 1966–1975 1000 9 9 0.9 NA 66.7 75
Heikkila et al.4 1961–1970 1069 5 NA 0.5 NA NA
Whyte et al.5 1980–1986 560 2 2 0.4 NA NA
Tan et al.6 1986–1991 255 6 NA 2.4 NA NA
Snijder et al.7 1977–1993 834 12 9 1.4 5 58 58
Lacasse et al.8) 1987–1990 399 3 NA 0.8 NA NA
Massard et al.9 1986–1997 2000 20 20 1.0 NA 38.7 51.30
Ruffini et al.10 1993–2002 1090 5 5 0.5 NA NA
Kawaguchi et al.11 1976–2003 4493 9 9 0.2 1 63
Collaud et al.12 1992–2000 584 3 3 0.5 2 100 100
Fernanez et al.13 1993–1997 2994 52 45 1.7 NA NA
Total 15,738 138 114 0.9
CIS, carcinoma in situ.
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margin out of a group of 20 patients with incomplete R1
resections out of 399 patients who had participated in a
multicenter randomized staging trial (incidence 0.75%).
The largest experience from a single institution re-
ported to date is that of Massard et al.9 from Strasbourg.
Twenty cases of CIS at the margin were identified in a
database of approximately 2000 resections performed over a
period of 11 years. These made up one-half of a population of
R1 resections which all together accounted for less than 2%
of all resections performed during that period. All 20 CIS
cases were squamous cell carcinomas: 13 were of N0 status,
6 were N1, and only 1 was N2. Ten of the 20 patients had
more than one primary cancer before or after their recorded
resection. Survival at 5 years was 38.7% for the 20 but rose
to 51.3% for the N0 subset. Adjuvant radiation therapy was
given in 17 of 20 patients, and the authors suggest that this
may have been deleterious in this group of patients. As all
previous authors have concluded, they observed that CIS at
the margin did not influence survival per se. At the time this
series was reported, in Strasbourg, the management of pa-
tients with CIS at the margin was for close follow-up with
serial CT and bronchoscopy. Photodynamic therapy was
being evaluated in the patients where early invasive cancer
was identified during such follow-up.
In 2004, a group from Torino described their experi-
ence with associated preinvasive lesions in 1090 patients
resected for lung cancer in a 10-year period. CIS at the
resected margin was only seen in five patients, all of squa-
mous histology. Two were treated with adjuvant radiother-
apy. At the time of their report, two were alive free of disease
2 and 5 years after surgery and three had died of systemic
metastases at 1, 2, and 3 years. Local recurrence rates were
not mentioned in this small group of patients.10
In analyzing 74 patients with microscopic residual
tumor at their bronchial margin out of 4493 patients who had
undergone lung cancer resection at the National Cancer
Center Hospital in Tokyo, Kawaguchi et al.11 noted 9 with
R1(is), all with squamous cell carcinoma histology, whose
5-year survival was 63%. Other R1 groups divided along the
patterns described by Soorae and Stevenson2 as patients with
direct mucosal extension by invasive cancer (n  11) or
lymphatic permeation and involvement of peribronchial tis-
sues (n  54) had 5-year survival rates of 0% and 10%,
respectively. Only one of the nine patients developed local
recurrence (11%) and he was one of the five who had been
given adjuvant radiation therapy. Contrary to the other pa-
tients with R1 disease in their series, the presence of CIS at
the margin did not increase the risk of developing a postop-
erative bronchopleural fistula.
Two more series were reported in 2009. The first by
Collaud et al.12 from Geneva described three cases of CIS at
the resection margin in a series of 35 patients with R1
resections out of the 584 consecutive interventions in 8 years.
All three had N0 NSCLC and survived beyond 5 years
without additional treatment. The other retrospective study
reported in 2009 was from the Bronchogenic Carcinoma
Cooperative Group of the Spanish Society of Thoracic Sur-
gery (GCCB-S). From 1993 to 1997, 2994 patients underwent
thoracotomy in the management of their NSCLC by the
members of the GCCB-S, and 80 had bronchial stump in-
volvement, 72 surviving beyond 30 days after surgery. Of
these, 52 had CIS at their margins and their reported median
survival was only 25 months, likely a reflection of the fact
that 29 of these had stages III or IV at surgery. Unfortunately,
the data reported in the manuscript does not allow an in-depth
analysis of these 52 cases.13
Finally, in a related but different review presented in
Barcelona at the IASLC 11th World Lung Cancer Conference
in 2005, Aubert et al.16 presented a retrospective study of
1501 patients resected for stages I to IIIA NSCLC. CIS at or
in the vicinity of the bronchial margin had been identified in
126 cases, and the authors concluded that the presence of CIS
at or near the margin had no negative affect on long-term
survival. The published abstract does not contain enough
information, however, to further evaluate their findings.
It is of interest only to note that, in a recent article
published in 2009, Riquet et al.17 excluded R1(is) cases when
studying the impact of R1 bronchial margins in a series of
4026 patients who had had R0-R1 resections from 1984 to
2006.
RESULTS
Thus, it seems that the presence of CIS at the resected
bronchial margin is a rare reported event, especially in lung
cancer cases with histology other than squamous cell carci-
noma. From the reports where survival was analyzed specif-
ically for patients with CIS at their bronchial margin, it seems
that the presence of R1(is) does not negatively impact on the
survival of our patients contrary to other R1 situations such as
patients with direct mucosal extension by invasive cancer or
lymphatic permeation and involvement of peribronchial tis-
sues where survival is generally poor.2,7,11
The data reviewed unfortunately does not allow clearly
separating the margin status from other prognostic factors
such N status. Two reports confined their analysis to patients
with N0 disease7,12 for a total of 15 patients. Another series
describes an overall 5-year survival of 38.7% for the 20
patients reported and a survival of 51.3% when restricting
their analysis to patients with N0 disease, without specifically
mentioning the 5-year survival rates of patients with N1 or
N2 disease. In addition, the report from Finland compared the
survival of all patients with R1 bronchial margins (including
five cases with R1(is)) to those with R0 margins. In both
groups, the survival of patients with stage I carcinoma was
reported as significantly better than stage III. Also, the sur-
vival rates were identical in the two groups when evaluated
by TNM.4 Indirect evidence thus suggests that the survival is
driven by the presence or absence of regional nodal involve-
ment in these patients and not by the presence or absence of
CIS at their margin.
It is apparent from this review that the actual literature
addresses solely the behavior and prognosis of squamous CIS
at the bronchial margins and that there is no information
available at this time on the presence of the new proposed
concept of adenocarcinoma in situ at resection margins.18 In
addition, there are insufficient data to conclude on the behav-
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ior of CIS at the circumferential margins of resected periph-
eral adenocarcinomas. Of the 124 literature cases where the
histology of the primary tumor is reported, 114 were of
squamous histology (92%) (Table 1).
Finally, there are almost no data in these articles de-
scribing whether the CIS at the bronchial margin was asso-
ciated with a peripherally located cancer or whether it was in
proximity to an adjacent or nearby centrally located tumor.
As such, it is impossible to address the hypothesis that maybe
these two different scenarios should be considered and coded
differently. For example, a centrally located squamous cell
cancer with adjacent CIS at the bronchial margin could be
coded R1(is). A peripheral tumor of any histology resected by
lobectomy where the bronchial resection margin expresses
CIS possibly could be coded as two different tumors: the
peripheral lesion being R0 and the second Tis R1(is).
DISCUSSION
Skewed Population?
The series listed earlier only address the follow-up,
recurrence patterns, and survival of individuals who were
found to have CIS at the bronchial margin identified on final
pathological analysis of the resected specimen. As such, it is
unfortunately impossible from this review to comment on the
behavior of individuals who may have initially had CIS
identified by frozen section evaluation during surgery and in
whom the surgeon elected to take the resection to a higher
level in the bronchial tree to obtain a true R0 bronchial
resection.
A Paradox?
In 1956, Habein et al.19 in discussing cancer recurrence
in the bronchial stump suggested that after pneumonectomy
“the finding of metaplastic epithelium near the carina is of
nearly as much prognostic significance as is the presence of
frank carcinoma in this region.” In 1959, Cotton20 noted that
30% of the cases he reviewed after resection harbored “epi-
thelial metaplasia” in the vicinity of the bronchial margins
and thought it would be wise “to remove the tumors as widely
as possible to avoid leaving behind potentially dangerous
areas of epithelial change.” The influential work of Auerbach
et al.21 demonstrated that preinvasive lesions (including CIS)
were frequent in the bronchial epithelium of smokers and of
patients with lung cancer. As a result of this study and others
that followed, the concepts of field carcinogenesis and of the
gradual and stepwise progression of early epithelial changes
to metaplasia, mild, moderate, severe dysplasia toward CIS,
and micro invasive bronchial cancers have developed.22–23
More recent reports on the follow-up of CIS identified
by autofluorescence bronchoscopy in populations considered
at high risk of developing lung cancer suggested that the
majority of these lesions will indeed progress to invasive
cancer on relatively short follow-up with some reporting 20%
of progressions occurring in the first year and 66% within 36
months.24–26 This observation certainly does not correspond
to the postoperative observations described earlier. Are we
dealing with the same disease? Is the pathology described as
CIS in these reported retrospective surgical series really CIS
as a panel of experts would define it today?25 Is there a
possibility that CIS at the bronchial resection margins re-
gresses spontaneously after removal of the nearby cancer as
some have suggested: either from spontaneous regression
after smoking cessation or by rendering the area relatively
ischemic thus promoting regression, as a result of a local
scarring phenomenon or through unknown local immuno-
logic pathways?2,3,23 Spontaneous regression of preneoplastic
changes has been reported in 52% of lesions seen in nonsur-
gical high-risk individuals who had been found to harbor such
changes on autofluorescence bronchoscopy in a recent report
by Breuer et al.27 from Amsterdam. An excellent review by
Banerjee22 in the Journal of Thoracic Oncology also recently
emphasized that there is a discrepancy between the preva-
lence of preinvasive bronchial lesions and that of lung cancer,
suggesting that not all lesions will develop into invasive
cancer.
Adjuvant Radiotherapy Issues
There is very little and conflicting reports documenting
the role of adjuvant radiotherapy in the management of
residual CIS at the bronchial resection margin. Heikkila et al.4
believed that adjuvant radiation therapy accounted for an
improved survival after incomplete R1 resections. Massard et
al.9 also reported a low rate of local recurrence with the use
of postoperative radiation therapy in marginal CIS, 15%, in
contrast to more than 50% in a series by Snijder et al.7: most
patients in the Massard series received adjuvant radiotherapy,
but their data also suggested a deleterious effect on long-term
survival. This is similar to what was seen in the PORT
meta-analysis and we may suspect that the weaknesses of the
radiation technique used were similar to those used in the
PORT randomized trials.28 Others have described the use of
PORT after sleeve resections when CIS was seen at one of the
bronchial margins.29 Nevertheless, at this time, there is in-
sufficient data to draw any conclusion on the role of adjuvant
external beam radiation therapy in this situation. Considering
this and taking into account the favorable survival and the low
local recurrence rates reported, close follow-up might be the best
alternative with a dedicated treatment in case of relapse. One
series, however, has suggested very little role for surveillance
white light bronchoscopy in these individuals owing to its low
returns and the limited impact this procedure had in their hands
in modifying patient management positively.5
Alternative experimental approaches mentioned, with-
out published results to date, have included endobronchial
brachytherapy or other novel endoluminal therapeutic modal-
ities such as laser therapy with or without photodynamic
therapy.9,30
Pathology Issues
By current standards squamous dysplasia in the bron-
chial mucosa is not regarded as a positive margin but CIS is.
The debate being considered in this article is whether CIS
should be regarded as a negative margin (R0) or microscop-
ically positive margin (R1(is)).
R1 positive margins can be divided into (1) inner
bronchial wall which can take the form of mucosal CIS or
invasion of submucosal tissues; (2) outer bronchial wall and
Vallie`res et al. Journal of Thoracic Oncology • Volume 6, Number 10, October 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1620
peribronchial which can take the form of direct extension of
the primary tumor or invasion from nearby metastatic tumor
into lymph nodes; (3) lymphatic invasion can occur in the
submucosal or peribronchial lymphatics; (4) in addition, one
can have detached floating fragments of tumor within the
bronchial lumen from intraluminal polypoid tumors without
attachment at the margin (Table 2). Patients with a micro-
scopically positive margin who have tumor either in the
peribronchial tissues or lymphatics seem to have a signifi-
cantly worse prognosis than those with CIS alone.2
Squamous cell CIS is a preinvasive lesion that occurs
within the mucosa of major bronchi, and except for cases
detected in the setting of screening, it is most frequently an
incidental histologic finding in association with invasive
squamous cell carcinomas.31 It is at the most severe end of the
continuum of mild, moderate, severe dysplasia and CIS. This
spectrum comprises a constellation of histologic changes
including nuclear to cytoplasmic ratio, nuclear atypia, mitotic
activity, and thickness of the cytologic changes within the
bronchial mucosa. These changes are most often found at the
spurs of bronchial bifurcation. In addition, changes from
dysplasia/CIS to normal mucosa are often abrupt.32
One report suggests reasonable reproducibility between
pathologists among the various categories of squamous pre-
invasive lesions in the 1999 and 2004 WHO classification
when looking at photomicrographs and high power fields of
selected lesions.33 However, it can be difficult to separate
severe dysplasia from CIS, particularly on a frozen section.
Maygarden et al.34 analyzed 405 cases in which frozen
sections of bronchial margins were performed in 268 (66%)
of cases. They found 90.6% true-negative cases, 16 true-
positive cases (6.0%), 4 (1.5%) false-positive cases, and 5
(1.9%) false-negative cases. The false positives included
squamous metaplasia that was called dysplasia/CIS (n  1),
radiation changes thought to be suspicious for carcinoma
(n  1), and benign peribronchial lymphocytes were misin-
terpreted as small cell carcinoma (n  2). There was poor
correlation between gross distance of tumor from the margin
and whether the margin was positive. Hofman et al.35 found
a discrepancy between frozen section and final histology in
11 of 21 (52%) cases with positive bronchial margins. Also,
false-negative bronchial margins were most often (9 of 15,
60%) of patients with peribronchial infiltration. Finally,
Weisel et al.36 found that frozen sections had 7 of 70 (10%)
false-negative rate in patients who underwent sleeve resection
of the main bronchus.
In 2005, Pasic et al.37 from Amsterdam reported on 11
patients referred to their program (denominator unknown) for
bronchoscopic follow-up after resection of Tis-1-2-3N0
NSCLC (10 squamous, 1 adenocarcinoma). These patients all
had had negative frozen section evaluation of their bronchial
margins at the time of resection but were found to have CIS
on final pathology review of the bronchial margin. None of
these patients received adjuvant therapy for their CIS, but all
were followed closely by serial LIFE endoscopies and yearly
high-resolution CT scans. Three of the 11 developed stump
recurrence (28%) within 5 to 15 months of resection. Three
more developed a new primary squamous cell cancer, away
from the stump, within 11 to 28 months of resection. In this
article, the authors introduced a new pathological subclassi-
fication of CIS that is said to be simple and reproducible and
that appeared to better subdefine the risks of patients with CIS
at the margin: (1) CIS-S with CIS confined only to the surface
epithelium; (2) CIS-D with involvement of the surface epi-
thelium and into the bronchial gland ducts but not deeper; (3)
CIS-A where the changes involve the surface epithelium, the
glandular ducts, and the glandular acini. In their limited
series, all stump recurrences were seen in the three patients
with CIS-A; none of the six patients with CIS-D or the two
patients with CIS-S had stump recurrence.37 Whether CIS-A
could be interpreted as invasive cancer by some and thus
account for its related propensity to develop stump recurrence
is a possibility. The subclassification suggested by Pasic et al.
and listed above is certainly intriguing and warrants further
validation.
Recent reports suggest the possibility of selecting
higher risk preinvasive lesions by using predictive molecular
markers.38 The use of such technology may also one day
possibly help us better define the potential invasive behavior
of CIS at bronchial stumps or elsewhere in our patients’
airways.
CONCLUSIONS
CIS at the surgical bronchial margin is a rare reported
event in our literature. As per the AJCC/UICC TNM defini-
tion, the presence of CIS at the margin is considered a
positive microscopic margin (R1(is)). There seems to be little
evidence to support this when resection has been undertaken
for squamous pathology. Indeed, after resection for squamous
cell cancer, in contrast to the other more common R1 types
bronchial positive margins, the presence of CIS does not
seem to negatively affect the prognosis after resection, and
there is no evidence that adding treatment beyond initial
resection favorably affects the prognosis of these resected
lesions. There are insufficient data to comment or conclude
on the significance of CIS at the margin of resections for
nonsquamous histologies.
Analysis of the existing literature does not allow us to
recommend any management guidelines when CIS is identi-
fied by frozen or permanent sections at the bronchial margin.





Outer bronchial wall and peribronchial or perivascular tissues
Direct extension of primary tumor
Invasion from nearby lymph nodes with metastases
Lymphatic permeation: submucosal or peribronchial lymphatics
Detached luminal floating tumor fragments from papillary or polypoid
tumor without attachment to the bronchial wall
CIS, carcinoma in situ.
Modified from J Thorac Cardiovasc Surg 1979;78:175–180 and Thorax 1982;37:
492–495.
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An improved pathologic subclassification of CIS at the mar-
gin may allow for better characterization of the behavior of
these tumors and possibly a subset of CIS margins that we
could consider for more or less aggressive management in the
future. The now accruing IASLC Lung Cancer Staging Pro-
spective Project will be collecting data elements pertaining to
this question of CIS at the bronchial resection margin and
may help to better determine an optimal approach to these
patients in the future.39
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